Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-09-05
2006-09-05
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S456000, C514S04400A
Reexamination Certificate
active
07101540
ABSTRACT:
Methods are disclosed for delivering a heterologous gene to a cell body of a neuron by contacting a muscle tissue innervated by the neuron with a viral vector comprising a heterologous gene, wherein the viral vector enters said neuron and is retrogradely moved to the cell body. Additionally, methods for expressing secreted proteins from a nerve cell body as well as methods for treating neurodegenerative disorders such as amyotrophic lateral sclerosis are described.
REFERENCES:
patent: 4955892 (1990-09-01), Daniloff
patent: 5092871 (1992-03-01), Aebischer et al.
patent: 6632427 (2003-10-01), Finiels et al.
patent: 2002/0031493 (2002-03-01), Horellou et al.
patent: 2003/0050273 (2003-03-01), Ozawa et al.
patent: 2003/0118552 (2003-06-01), Kaspar et al.
patent: WO 200142481 (2001-06-01), None
Baumgartner et al., “Neuroprotection of spinal motorneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor,” Exp. Neurol. 153(1): 102-112, Sep. 1998).
Yamashita et al., “Bcl-2 expression by retrograde transport of adenoviral vecotrs with Cre-IoxP recombination system in motor neurons of mutant SOD1 transgenic mice,” Gene Ther. 8(13): 977-986, Jul. 2001.
Yamashita et al., “Effect on motor neuron survival in mutant SOD1 (G93A) transgenic mice by Bcl-2 expression using retrograde axonal transport of adenoviral vectors,” Neurosci. Lett. 328(3): 289-293, Aug. 16, 2002.
Wang et al., “Neuroprotective effect of glial cell line-derived neurotrophic neurotrophic factor mediated by an adeno-associated virus in a transgenic animal model of amyotrophic lateral sclerosis,” J. Neurosci. 22(16): 6920-6928, Aug. 15, 2002.
Kaspar et al., “Targeted retrograde gene delivery for neuronal protection,” Mol. Ther. 5(1): 50-56, Jan. 2002.
Aebischer & Ridet, Recombinant Proteins for Neurodegenerative Diseases: The Delivery Issue, Trends Neurosciences, 2001 24(9):533-40.
Antonawich et al., BCL-2 Transduction, Using a Herpes Simplex Virus Amplicon, Protects Hippocampal Neurons from Transient Global Ischemia, Academic Press, Experimental Neurology 156, 130-137 (1999).
Bartlett et al., Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors, Journal of Virology, Mar. 2000, p. 2777-2785.
Bartlett et al., Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain, Human Gene Therapy 9:1181-1186 (May 20, 1998).
Blomer et al., BCL-XL Protects Adult Septal Cholinergic Neurons from Axotomized Cell Death, Proc. Natl. Acad. Sci. USA vol. 95, pp. 2603-2608, Mar. 1998.
Calamandrei and Alleva, Neuronal Growth Factors, Neurotrophins and Memory Deficiency, Behav Brain Res 1995 Jan. 23;66(1-2):129-32.
Carver and Barness, Trophic Factors for the Gastrointestinal Tract, Clin Perinatol (1996) 23(2):265-85.
Cleveland et al., From Charcot to SOD1: Mechanisms of Selective Motor Neuron Death in ALS, Neuron, vol. 24, 515-520, Nov. 1999.
DeFalco et al., Virus-Assisted Mapping of Neural Inputs to a Feeding Center in the Hypothalamus,Science291:2608-2613 (Mar. 2001).
Dolorfo & Amaral, Entorhinal Cortex of the Rat: Topographic Organization of the Cells of Origin of the Perforant Path Projection to the Dentate Gyrus, The Journal of Comparative Neurology 398:25-48 (1998).
Duvoisin, Roger C., Overview of Parkinson's Disease, Annals New York Academy of Sciences, pp. 187-193.
Fawcett J.W., Spinal Cord repair: From Experimental Models to Human Application, Spinal Cord (1998) 36(12):811-7.
Gomez-Isla et al., Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease, The Journal of Neuroscience, Jul. 15, 1996, 16(14):4491-4500.
Gonzalez-Garcia, BXL-X is Expressed in Embryonic and Postnatal Neural Tissues and Functions to Prevent Neuronal Cell Death, Proc. Natl. Acad. Sci, USA, vol. 92, pp. 4304-4308, May 1995.
Hefti et al., Development of Neurotrophic Factor Therapy for Alzheimer's Disease, Ciba Found Symp. (1996)196:54-69.
Kaplitt, et al., Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain, Nature Genetics, vol. 8, Oct. 1994.
Kishi & Cowan, A Quantitative EM Autoradiographic Study of the Commissural and Associational Connections of the Dentate Gyrus in the Rat, Anat. Embryol. 160, 173-186 (1980).
Koliatsos V.E., Biological Therapies for Alzheimer's Disease: Focus on Trophic Factors, Crit Rev Neurobiol (1996) 10(2):205-38.
Latchman & Coffin, Viral Vectors for Gene Therapy in Parkinson's Disease, Rev Neurosci. (2001) 12(1):69-78.
Monahan & Samulski, AAV Vectors: is Clinical Success on the Horizon?, Gene Therapy (2000) 7, 24-30.
Monahan & Samulski, Adeno-Associated Virus Vectors for Gene Therapy: More Pros than Cons?, Mol Med Today. (2000) 6(11):433-40.
Offen et al., Apoptosis as a General Cell Death Pathway in Neurodegenerative Diseases, J Neural Transm Suppl. (2000) 58:153-66.
Peterson et al., Central Neuronal Loss and Behavioral Impairment in Mice Lacking Neurotrophin Receptor p. 75, The Journal of Comparative Neurology 404:1-20 (1999).
Qing et al., Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2 Nature Medicine, vol. 5, No. 1, pp. 71-77, Jan. 1999.
Senut et. al., Intraneuronal Aggregate Formation and Cell Death after Viral Expression of Expanded Polyglutamine Tracts in the Adult Rat Brain,J Neurosci. 2000 Jan. 1; 0(1):219-229.
Smith-Arica & Bartlett, Gene Therapy: Recombinant Adeno-Associated Virus Vectors, Curr Cardiol Rep. (2001) 3(1):43-9.
Snyder, et al. Effective and Stable Adeno-Associated Virus-Mediated Transduction in the Skeletal Muscle of Adult Immunocompetent Mice,Hum Gene Ther. Nov. 1, 1997 8(16):1891-900.
Summerford et al., αVβ5 Integrin: a Co-Receptor for Adeno-Associated Virus Type 2 Infection, Nature Medicine, vol. 5, No. 1, pp. 78-82, Jan. 1999.
Terenghi G., Peripheral Nerve Regeneration and Neurotrophic Factors, J Anat (1999) 194 (Pt 1):1-14.
Yamada et al., Herpes Simplex Virus Vector-Mediated Expression of BCL-2 Prevents 6-Hydroxydopamine-Induced Degeneration of Neurons in the Substantia Nigrain Vivo, Proc. Natl. Acad. Sci., vol. 96, pp. 4078-4083, Mar. 1999.
Yuen EC, The Role of Neurothrophic Factors in Disorders of Peripheral Nerves and Motor Neurons, Phys Med Rehabil Clin N Am. (2001) 12(2):293-306, viii.
Yuen et al., Therapeutic Potential of Neurotrophic Factors for Neurological Disorders, Am. Neurol. (1996) 40(3):346-54.
Xiao et al., Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus, Journal of Virology, Mar. 1998, p. 2224-2232.
Xiao et al., Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous System, Experimental Neurology 144, 113-124 (1997).
Gurney et al., Motor Neuron Degeneration in Mice That Express a Human Cu,Xn Superoxide Dismutase Mutation, Science, vol. 264, p. 1772-1775, Jun. 17, 1994.
Peel et al., Adeno-Associated Virus Vectors: Activity and Applications in the CNS, Journal Neuroscience Methods 98 (2000) 95-104.
Dorland's Illustrated Medical Dictionary, 28thEdition, W.B. Saunders Co., Philadelphia, PA, 1994, pp. 832, 1131, 1361.
Hsich et al., “critical issues in gene therapy for neurologic disease,” Human Gene Therapy 13:579-604, Mar. 20, 2002.
Orkin et al., Report and Recommendations of the Panel to Asses the NIH Investment in Research on Gene Therapy, Issued Dec. 7, 1995 by the US National Inst. Of Health, Bethesda, MD.
Peterson et al., “Prophylactic neuroprotection of injured entorhinal cortical neurons by retrograde in vivo gene delivery of an anti-apoptotic transgene,” European Journal of Neuroscience 12 (Suppl. 11): 233, Abstract 110.13, Jun. 2000.
Rosenberg et al., “Gene therapist, heal thyself,” Science 287: 1751, Mar. 10, 2000.
Simon et al., “bcl-2 gene therapy exacerbates excitotoxicity,” Human Gene Therapy 10:1715-1720, Jul. 1, 1999.
Verma et al., “Gene therapy—promises, problems and prospe
Gage Fred H.
Kaspar Brian K.
Klarquist & Sparkman, LLP
Priebe Scott D.
The Salk Institute For Biological Studies
LandOfFree
Targeted retrograde gene delivery to motor neurons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted retrograde gene delivery to motor neurons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted retrograde gene delivery to motor neurons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559696